Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (15)
Similar to Mesa 3.1 bernardino alcázar
Similar to Mesa 3.1 bernardino alcázar (20)
More from FERRER EPOCSITE PRO
More from FERRER EPOCSITE PRO (20)
Recently uploaded
Recently uploaded (20)
Mesa 3.1 bernardino alcázar
- 2. Mesa 3. Tratamiento Dr. Bernardino Alcázar Navarrete Hospital de Alta Resolución de Loja. Granada
- 3. Mesa 3. Tratamiento Mesa 3 Tratamiento
- 4. Mesa 3. Tratamiento GOLD guidelines, 2015
- 5. Mesa 3. Tratamiento Miravitlles et al. Arch Bronconeumol 2014
- 6. Mesa 3. Tratamiento Bateman et al. ERJ 2013
- 7. Mesa 3. Tratamiento Dransfield, Lancet Resp Med 2013
- 8. Mesa 3. Tratamiento Sin et al, Thorax 2010
- 9. Mesa 3. Tratamiento Pascoe, Lancet Resp Med 2015
- 10. Mesa 3. Tratamiento Magnussen et al. NEJM 2014
- 12. Mesa 3. Tratamiento Dr. José Luis López-Campos I [SEPAR] Utilidad de la vacunación antineumocócica de 13 serotipos en la prevención de exacerbaciones graves de EPOC I [ATS] QVA 149 Improves Lung Function To A Greater Extent Than Monocomponents In Patients With Moderate-To- Severe COPD: The FLIGHT 1 Study
- 13. Mesa 3. Tratamiento Dr. Joan Serra I [ATS] Effects Of 6 Weeks’ Treatment With Once-Daily Tiotropium And Olodaterol Fixed-Dose Combination On Inspiratory Capacity And Exercise Endurance In Patients With COPD: The MoractoTM Studies I [ATS] Withdrawal Of Inhaled Corticosteroids And Exacerbations Of COPD:The WISDOM Phenotyping Substudy I [ERS] Triple therapy of umeclidinium and inhaled corticosteroid/long-actingβ2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients
- 14. Mesa 3. Tratamiento Dr. Juan Antonio Riesco I [ATS] Inhaled Corticosteroids And Risk Of Incident Pneumonia And Mortality In Chronic Obstructive Pulmonary Disease (COPD) Patients: A Systematic Review And Meta-Analysis I [ATS] COPD Patient Clusters That Benefit Most From Fluticasone Furoate Added To Vilanterol (FF/VI) vs Vilanterol (VI) I [ERS] Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial I [ERS] Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
- 15. Mesa 3. Tratamiento Dr. Carlos Amado I [ATS] Stepwise Withdrawal Of Inhaled Corticosteroids in COPD Patients Receiving Dual Bronchodilators: Lung Function Reduction In The WISDOM Study I [ERS] Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials I [ATS] QVA 149 Provides Superior Improvement In Lung Function vs Its Monocomponents In Patients With Moderate- To-Severe COPD: The FLIGHT 2 Study
- 16. Mesa 3. Tratamiento Muchas gracias por su atención